|01/09/18||GBT Receives FDA Breakthrough Therapy Designation for Voxelotor for Treatment of Sickle Cell Disease (SCD)|
|Voxelotor is First Investigational Treatment for SCD to Receive Breakthrough Therapy Designation
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to voxelotor (previously called GBT440) for the treatment of sickle cell disease (SCD). Voxelotor is being developed as a disease-modifying therapy for SCD and previously... |
|01/03/18||GBT to Present at the 36th Annual J.P. Morgan Healthcare Conference|
|SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 7:30 a.m. Pacific Time.
The presentation and Q&A session will be webcast live and available for replay from GBT’s website at www.gbt.com in the Investors section.
GBT is a clinical-stage biopharmaceutical company determined to discover, deve... |
|12/22/17||GBT Appoints Wendy L. Yarno to Board of Directors|
|SOUTH SAN FRANCISCO, Calif., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the appointment of Wendy L. Yarno to the company’s board of directors. Ms. Yarno has more than 25 years of experience in the biopharmaceutical industry, including serving as chief marketing officer at Merck & Co. Inc.
“Wendy is an accomplished biopharmaceutical executive with a proven track record in building and leading organizations, and has significant exp... |
|12/15/17||Global Blood Therapeutics Prices a $100.0 Million Common Stock Public Offering|
|SOUTH SAN FRANCISCO, Calif., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need, today announced the pricing of its underwritten public offering of its common stock for gross proceeds of approximately $100.0 million, before deducting the underwriting discounts and commissions... |